Choline alfoscerate (Logacer) injections 250 mg/ml 4 ml – [10 ampoules]

Description

Logaczer Pharmacodynamics
Choline alphoscerate is a cholinomimetic of central action with predominant influence on the central nervous system. The drug contains 40.5% of choline, which is released from the compound in the brain; choline is involved in the biosynthesis of acetylcholine (one of the main mediators of nerve excitation). Alphoscerate is biotransformed to glycerophosphate, which is a precursor of phospholipids. Acetylcholine has a positive effect on nerve impulse transmission, and glycerophosphate participates in the synthesis of phosphatidylcholine (a membrane phospholipid), resulting in improved membrane elasticity and receptor function. Choline alphoscerate increases cerebral blood flow, enhances metabolic processes and activates structures of the reticular formation of the brain, as well as restores consciousness after traumatic brain injury. It has a preventive and corrective effect on the factors of involutional psychoorganic syndrome, such as changes in the phospholipid composition of neuronal membranes and decreased cholinergic activity. Thus, pharmacodynamic studies have shown that choline alphoscerate acts on: synaptic, including cholinergic transmission of nerve impulse (neurotransmission); neuronal membrane plasticity; receptor function.

Indications
– Psycho-organic syndrome against the background of involutional and degenerative processes in the brain;
– consequences of cerebrovascular insufficiency or primary and secondary cognitive disorders in elderly people, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, reduced concentration of attention;
– behavioral and affective disorders in old age: emotional lability, increased irritability, decreased interest;
– senile pseudomelancholia.

Contraindications
– Hypersensitivity to choline alphoscerate;
– Pregnancy, breast-feeding;
– Children under 18 years of age.
Caution
There is no data on the necessity of using the drug with caution.
Administration during pregnancy and breast feeding period.
Application of the drug during pregnancy and breast-feeding is contraindicated.

Dosage and administration method

• The drug is administered intramuscularly or intravenously (dropwise, slowly).
• Adults. Intramuscularly or intravenously at a dose of 1000 mg (1 ampoule) per day.
• During intravenous administration the content of one ampoule (4 ml) is diluted in 50 ml of 0.9% sodium chloride solution, infusion rate is 60-80 drops per minute.
• The duration of treatment is usually 10 days. Doses and duration of treatment, if necessary and if well tolerated, may be increased by attending physician depending on clinical picture, peculiarities of the disease course, age and drug tolerance.
• Children. The drug is contraindicated in children under 18 years old.